Fokal Serebellar Enfarktlı Fare Hayvan Modelinde Rho-Kinaz İnhibitörlerinin Etkinliği
Aykan Dilmen, Sanem Aslıhan
xmlui.mirage2.itemSummaryView.MetaDataShow full item record
According to AHA 2015, stroke is the fifth leading cause of death and is a major cause of serious and long term disability. Cerebellar strokes are account for 3% of all strokes. Early diagnosis and treatment of strokes affecting posterior circulation of the brain is very important. Misdiagnosis may cause serious disability or death. Since cerebellum has cognitive functions beyond motor and coordination functions, patients with cerebellar stroke may present with wide and different kind of symptoms. Thrombolytics is the major medical treatment in stroke which is the same treament for cerebellar stroke. The major side effect of thrombolytics is intracerebral hemorrhage which creates serious life threat. Newly developing ROCK inhibitors have been put forward as a treatment for stroke. In our study, we aimed to investigate the effect of focal cerebellar ischemia on the neurological recovery and infarct volume by applying the ROCK inhibitor, fasudil, 24 hours after ischemia for twice a day and continued for 2 weeks. Focal cerebellar ischemia was induced by nitric oxidase synthetase inhibitor enjection into lobule IV-V. In focal cerebellar ischemia mice (n=17, sham group n=21), significant changes were observed in footprint, gridwalk (especially in the forefoot), and static rod test, which shows altered balance and motor coordination compared to shame, but there was no difference in cognitive tests such as morris water maze, Barnes maze and and new object recognition test. In mice receiving Fasudil treatment (n=10, vehicle group n=9), improvement in gridwalking test and a 32% reduction in infarct volume were observed. In conclusion, the cerebellar infarct model that we have made for the first time in the literature gives neurological findings, and the effects of neurological and histologic recovery are observed with fasudil therapy applied 24 hours after ischemia.